MX2019008348A - Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas. - Google Patents
Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas.Info
- Publication number
- MX2019008348A MX2019008348A MX2019008348A MX2019008348A MX2019008348A MX 2019008348 A MX2019008348 A MX 2019008348A MX 2019008348 A MX2019008348 A MX 2019008348A MX 2019008348 A MX2019008348 A MX 2019008348A MX 2019008348 A MX2019008348 A MX 2019008348A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- against anti
- idiotypic
- antibodies against
- idiotypic antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
- C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- G01N33/686—Anti-idiotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70532—B7 molecules, e.g. CD80, CD86
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/26—Infectious diseases, e.g. generalised sepsis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La invención proporciona anticuerpos antiidiotipo contra anticuerpos anti-PD-L1 y métodos para usarlos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762447886P | 2017-01-18 | 2017-01-18 | |
US201762452934P | 2017-01-31 | 2017-01-31 | |
PCT/US2018/014099 WO2018136553A1 (en) | 2017-01-18 | 2018-01-17 | Idiotypic antibodies against anti-pd-l1 antibodies and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019008348A true MX2019008348A (es) | 2019-10-21 |
Family
ID=61157331
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019008348A MX2019008348A (es) | 2017-01-18 | 2018-01-17 | Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas. |
Country Status (11)
Country | Link |
---|---|
US (1) | US11279762B2 (es) |
EP (1) | EP3571228A1 (es) |
JP (1) | JP7105238B2 (es) |
KR (1) | KR20190104411A (es) |
CN (1) | CN110167967B (es) |
AU (1) | AU2018211064A1 (es) |
CA (1) | CA3050009A1 (es) |
IL (1) | IL268051A (es) |
MX (1) | MX2019008348A (es) |
TW (1) | TW201831520A (es) |
WO (1) | WO2018136553A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP6949030B2 (ja) | 2016-01-08 | 2021-10-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Pd−1軸結合アンタゴニスト及び抗cea/抗cd3二重特異性抗体を用いたcea陽性がんの治療方法 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
CA3097178A1 (en) | 2018-04-17 | 2019-10-24 | Molecular Templates, Inc. | Her2-targeting molecules comprising de-immunized, shiga toxin a subunit scaffolds |
CN109021107B (zh) * | 2018-09-05 | 2020-08-28 | 江苏诺迈博生物医药科技有限公司 | 一种特异性结合人pd-l1的单克隆抗体及包含其的药物和试剂盒 |
CN115279793A (zh) | 2020-05-14 | 2022-11-01 | 安立玺荣生医(香港)有限公司 | 抗pd-l1抗体和抗pd-l1/il10融合蛋白 |
CN112285366B (zh) * | 2020-12-25 | 2021-06-08 | 南京广祺医药科技有限公司 | 一种测定血清中双特异性抗体BsAb的ELISA方法及应用 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE337223B (es) | 1967-05-23 | 1971-08-02 | Pharmacia Ab | |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US3645090A (en) | 1969-06-19 | 1972-02-29 | Citizen Watch Co Ltd | Day-date quick-adjuster for calender timepiece |
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
CA2116774C (en) | 1991-09-19 | 2003-11-11 | Paul J. Carter | Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies |
US6020208A (en) | 1994-05-27 | 2000-02-01 | Baylor College Of Medicine | Systems for surface-enhanced affinity capture for desorption and detection of analytes |
US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
NZ516848A (en) | 1997-06-20 | 2004-03-26 | Ciphergen Biosystems Inc | Retentate chromatography apparatus with applications in biology and medicine |
US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
NZ517906A (en) | 1999-10-04 | 2003-01-31 | Medicago Inc | Cloning of genomic sequences encoding nitrite reductase (NiR) for use in regulated expression of foreign genes in host plants |
US20020139751A1 (en) | 2001-02-20 | 2002-10-03 | Sheng Zhang | Microchip electrospray device and column with affinity adsorbents and use of the same |
AU2009333580B2 (en) | 2008-12-09 | 2016-07-07 | Genentech, Inc. | Anti-PD-L1 antibodies and their use to enhance T-cell function |
JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン,エルエルシー | B7−h1およびpd−1に結合する抗体およびその他の分子 |
EP2831119A1 (en) * | 2012-03-28 | 2015-02-04 | F. Hoffmann-La Roche AG | Anti-hcmv idiotypic antibodies and uses thereof |
SG10201701380TA (en) | 2013-03-15 | 2017-04-27 | Genentech Inc | Biomarkers and methods of treating pd-1 and pd-l1 related conditions |
KR20160030936A (ko) | 2013-07-16 | 2016-03-21 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법 |
CN105899535A (zh) * | 2013-12-17 | 2016-08-24 | 豪夫迈·罗氏有限公司 | 用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法 |
TWI680138B (zh) * | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | 抗pd-l1之人類抗體 |
CA2983282A1 (en) * | 2015-05-12 | 2016-11-17 | Genentech, Inc. | Therapeutic and diagnostic methods for cancer |
WO2016205566A1 (en) * | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
WO2016205551A2 (en) | 2015-06-16 | 2016-12-22 | The Regents Of The University Of California | Fzd7 specific antibodies and vaccines to treat cancer and control stem cell function |
-
2018
- 2018-01-17 MX MX2019008348A patent/MX2019008348A/es unknown
- 2018-01-17 CA CA3050009A patent/CA3050009A1/en not_active Abandoned
- 2018-01-17 AU AU2018211064A patent/AU2018211064A1/en not_active Abandoned
- 2018-01-17 CN CN201880006331.2A patent/CN110167967B/zh active Active
- 2018-01-17 WO PCT/US2018/014099 patent/WO2018136553A1/en unknown
- 2018-01-17 KR KR1020197024019A patent/KR20190104411A/ko not_active Application Discontinuation
- 2018-01-17 JP JP2019538318A patent/JP7105238B2/ja active Active
- 2018-01-17 EP EP18703142.2A patent/EP3571228A1/en active Pending
- 2018-01-18 TW TW107101891A patent/TW201831520A/zh unknown
-
2019
- 2019-07-14 IL IL268051A patent/IL268051A/en unknown
- 2019-07-15 US US16/511,323 patent/US11279762B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
TW201831520A (zh) | 2018-09-01 |
IL268051A (en) | 2019-09-26 |
JP7105238B2 (ja) | 2022-07-22 |
KR20190104411A (ko) | 2019-09-09 |
WO2018136553A1 (en) | 2018-07-26 |
AU2018211064A1 (en) | 2019-09-05 |
EP3571228A1 (en) | 2019-11-27 |
JP2020515238A (ja) | 2020-05-28 |
CN110167967B (zh) | 2022-08-05 |
US11279762B2 (en) | 2022-03-22 |
CN110167967A (zh) | 2019-08-23 |
US20190338034A1 (en) | 2019-11-07 |
CA3050009A1 (en) | 2018-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA202107931B (en) | Anti-tau antibodies and methods of use | |
MX2019008348A (es) | Anticuerpos idiotipo contra anticuerpos anti-pd-l1 y usos de estos solicitudes relacionadas. | |
MX2017000419A (es) | Anticuerpos anti-pd-l1 y sus usos de diagnóstico. | |
PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
PH12017500861A1 (en) | Anti-interleukin-33 antibodies and uses thereof | |
MX2019006334A (es) | Anticuerpos antitau y métodos de uso. | |
WO2018081648A8 (en) | ANTI-MIC ANTIBODIES AND METHODS OF USE | |
PH12017500322A1 (en) | Anti-her2 antibodies and immunoconjugates | |
MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
MY193661A (en) | Anti-tim3 antibodies and methods of use | |
EP4335874A3 (en) | Anti-hla-g antibodies and use thereof | |
TW201613963A (en) | Anti-JAGGED1 antibodies and methods of use | |
PH12020551336A1 (en) | Anti-klk5 antibodies and methods of use | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
PH12019501285A1 (en) | Antibodies and polypeptides directed against cd127 | |
MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
MX2017016169A (es) | Anticuerpos anti-her2 y metodos de uso. | |
PH12019501872A1 (en) | Anti-tryptase antibodies, compositions thereof, and uses thereof | |
MX2021002616A (es) | Anticuerpos agonistas anti receptor desencadenante expresado en celulas mieloides 2 (trem-2). | |
MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
MX2016015280A (es) | Anticuerpos anti-bromodesoxiuridina(brdu) y metodos de uso. | |
MX2023000617A (es) | Anticuerpos anti-notch2 y metodos de uso. | |
NZ744340A (en) | Anti-jagged1 antibodies and methods of use |